Efficacy of the oral pentavalent rotavirus vaccine in Mali

Vaccine

Volumn 30, Issue SUPPL. 1, 2012, Pages

  Sow, Samba O ^a   Tapia, Milagritos ^a,b   Haidara, Fadima C ^a   Ciarlet, Max ^c,e   Diallo, Fatoumata ^a   Kodio, Mamoudou ^a   Doumbia, Moussa ^a   Dembélé, Rokiatou D ^a   Traoré, Oumou ^a   Onwuchekwa, Uma U ^a   Lewis, Kristen D C ^d   Victor, John C ^d   Steele, A Duncan ^d   Neuzil, Kathleen M ^d   Kotloff, Karen L ^a,b   Levine, Myron M ^a,b  

^a Centre pour le Developpement des Vaccins   (Mali)

^b University of Maryland School of Medicine Center for Vaccine Development   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d PATH   (United States)

^e NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

Author keywords

Efficacy trial; Mali; Rotavirus vaccine; Severe gastroenteritis

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; NEUTRALIZING ANTIBODY; PLACEBO; ROTAVIRUS VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CULTURAL ANTHROPOLOGY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROENTERITIS; GENOTYPE; HEALTH CARE PERSONNEL; HUMAN; IMMUNOGENICITY; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MALI; MULTICENTER STUDY; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ROTAVIRUS GASTROENTERITIS; VIRUS ISOLATION;

ADMINISTRATION, ORAL; ANTIBODIES, VIRAL; DRUG TOXICITY; FEMALE; GASTROENTERITIS; HUMANS; IMMUNOGLOBULIN A; INFANT; MALE; MALI; PLACEBOS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SEVERITY OF ILLNESS INDEX; VACCINATION; VACCINES, ATTENUATED;

EID: 84859963644     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.094     Document Type: Article

References (49)

1. Black R.E., Cousens S., Johnson H.L., Lawn J.E., Rudan I., Bassani D.G., et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010, 375(9730):1969-1987.
2. Tate J.E., Burton A.H., Boschi-Pinto C., Steele A.D., Duque J., Parashar U.D., et al. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12(2):131-141.
3. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354(1):11-22.
4. Vesikari T., Matson D.O., Dennehy P., Van D.P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354(1):23-33.
5. Conclusions and recommendations from the Immunization Strategic Advisory Group. Wkly Epidemiol Rec 2006;81(1):2-11.
6. Meeting of the immunization Strategic Advisory Group of Experts, April 2009-conclusions and recommendations. Wkly Epidemiol Rec 2009;84(23):220-36.
7. Zaman K., Dang D.A., Victor J.C., Shin S., Yunus M., Dallas M.J., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376(9741):615-623.
8. Armah G.E., Sow S.O., Breiman R.F., Dallas M.J., Tapia M.D., Feikin D.R., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376(9741):606-614.
9. Gilchrist M.J., Bretl T.S., Moultney K., Knowlton D.R., Ward R.L. Comparison of seven kits for detection of rotavirus in fecal specimens with a sensitive, specific enzyme immunoassay. Diagn Microbiol Infect Dis 1987, 8(4):221-228.
10. DiStefano D.J., Kraiouchkine N., Mallette L., Maliga M., Kulnis G., Keller P.M., et al. Novel rotavirus VP7 typing assay using a one-step reverse transcriptase PCR protocol and product sequencing and utility of the assay for epidemiological studies and strain characterization, including serotype subgroup analysis. J Clin Microbiol 2005, 43(12):5876-5880.
11. Ruuska T., Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990, 22(3):259-267.
12. Ruuska T., Vesikari T. A prospective study of acute diarrhoea in Finnish children from birth to 2 1/2 years of age. Acta Paediatr Scand 1991, 80(5):500-507.
13. Miettinen O., Nurminen M. Comparative analysis of two rates. Stat Med 1985, 4(2):213-226.
14. Tapia M., Armah G.E., Breiman R., Dallas M., Lewis K., Sow S., et al. Primary and secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine 2012, 30(Suppl. 1):A79-A85.
15. Ciarlet M., Sani-Grosso R., Yuan G., Liu G.F., Heaton P.M., Gottesdiener K.M., et al. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine. Pediatr Infect Dis J 2008, 27(10):874-880.
16. Chang C.C., Chang M.H., Lin T.Y., Lee H.C., Hsieh W.S., Lee P.I. Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan. J Formos Med Assoc 2009, 108(4):280-285.
17. Kim D.S., Lee T.J., Kang J.H., Kim J.H., Lee J.H., Ma S.H., et al. Immunogenicity and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy infants in Korea. Pediatr Infect Dis J 2008, 27(2):177-178.
18. Ciarlet M., Schodel F. Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq. Vaccine 2009, 27(Suppl. 6):G72-G81.
19. Rodriguez Z.M., Goveia M.G., Stek J.E., Dallas M.J., Boslego J.W., DiNubile M.J., et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatr Infect Dis J 2007, 26(3):221-227.
20. Ciarlet M., He S., Lai S., Petrecz M., Yuan G., Liu G.F., et al. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. Pediatr Infect Dis J 2009, 28(3):177-181.
21. Armah G.E., Breimen R.F., Tapia M., Dallas M.J., Neuzil K.M., Binka F.N. Immunogenicity of the pentavalent rotavirus vaccine in African infants. Vaccine 2012, 30(Suppl. 1):A86-A93.
22. Lewis K., Dallas M., Victor J.C., Ciarlet M., Mast C.T., Ji M., et al. Comparison of two clinical severity scoring systems in two multi-center, developing country roatvirus vaccine trials in Africa and Asia. Vaccine 2012, 30(Suppl. 1):A159-A166.
23. Ellis A.A., Winch P., Daou Z., Gilroy K.E., Swedberg E. Home management of childhood diarrhoea in southern Mali-implications for the introduction of zinc treatment. Soc Sci Med 2007, 64(3):701-712.
24. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010, 362(4):289-298.
25. John T.J., Jayabal P. Oral polio vaccination of children in the tropics. I. The poor seroconversion rates and the absence of viral interference. Am J Epidemiol 1972, 96(4):263-269.
26. John T.J. Oral polio vaccination of children in the tropics. II. Antibody response in relation to vaccine virus infection. Am J Epidemiol 1975, 102(5):414-421.
27. John T.J., Christopher S. Oral polio vaccination of children in the tropics. III. Intercurrent enterovirus infections, vaccine virus take and antibody response. Am J Epidemiol 1975, 102(5):422-428.
28. Patriarca P.A., Wright P.F., John T.J. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991, 13(5):926-939.
29. Suharyono Simanjuntak C., Witham N., Punjabi N., Heppner D.G., Losonsky G., et al. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet 1992, 340(8821):689-694.
30. Su-Arehawaratana P., Singharaj P., Taylor D.N., Hoge C., Trofa A., Kuvanont K., et al. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J Infect Dis 1992, 165(6):1042-1048.
31. Gotuzzo E., Butron B., Seas C., Penny M., Ruiz R., Losonsky G., et al. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect Immun 1993, 61(9):3994-3997.
32. Lagos R., Fasano A., Wasserman S.S., Prado V., San M.O., Abrego P., et al. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J Infect Dis 1999, 180(5):1709-1712.
33. Hallander H.O., Paniagua M., Espinoza F., Askelof P., Corrales E., Ringman M., et al. Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children. Vaccine 2002, 21(1-2):138-145.
34. Levine M.M., Kotloff K.L., Barry E.M., Pasetti M.F., Sztein M.B. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol 2007, 5(7):540-553.
35. Serazin A.C., Shackelton L.A., Wilson C., Bhan M.K. Improving the performance of enteric vaccines in the developing world. Nat Immunol 2010, 11(9):769-773.
36. Czerkinsky C., Holmgren J. Enteric vaccines for the developing world: a challenge for mucosal immunology. Mucosal Immunol 2009, 2(4):284-287.
37. Levine M.M. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol 2010, 8:129.
38. Wang Y., Azevedo M., Saif L.J., Gentsch J.R., Glass R.I., Jiang B. Inactivated rotavirus vaccine induces protective immunity in gnotobiotic piglets. Vaccine 2010, 28(33):5432-5436.
39. Jiang B., Gentsch J.R., Glass R.I. Inactivated rotavirus vaccines: a priority for accelerated vaccine development. Vaccine 2008, 26(52):6754-6758.
40. Breiman R.F., Zaman K., Armah G., Sow S., Dang A.D., Victor J.C., et al. Analyses of health outcomes from the 5 sites particpating in the Africa and Asia clinical efficacy trials or oral pentavalent rotavirus vaccine. Vaccine 2012, 30(Suppl. 1):A24-A29.
41. Tate J.E., Panozzo C.A., Payne D.C., Patel M.M., Cortese M.M., Fowlkes A.L., et al. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatrics 2009, 124(2):465-471.
42. Chang H.G., Smith P.F., Tserenpuntsag B., Markey K., Parashar U., Morse D.L. Reduction in hospitalizations for diarrhea and rotavirus infections in New York state following introduction of rotavirus vaccine. Vaccine 2010, 28(3):754-758.
43. Tate J.E., Mutuc J.D., Panozzo C.A., Payne D.C., Cortese M.M., Cortes J.E., et al. Sustained decline in rotavirus detections in the United States following the introduction of rotavirus vaccine in 2006. Pediatr Infect Dis J 2011, 30(1 (Suppl.)):S30-S34.
44. Yen C., Tate J.E., Wenk J.D., Harris J.M., Parashar U.D. Diarrhea-associated hospitalizations among US children over 2 rotavirus seasons after vaccine introduction. Pediatrics 2011, 127(1):e9-e15.
45. Clarke M.F., Davidson G.P., Gold M.S., Marshall H.S. Direct and indirect impact on rotavirus positive and all-cause gastroenteritis hospitalisations in South Australian children following the introduction of rotavirus vaccination. Vaccine 2011, 29(29-30):4663-4667. [Epub 2011 May 14].
46. Macartney K.K., Porwal M., Dalton D., Cripps T., Maldigri T., Isaacs D., et al. Decline in rotavirus hospitalisations following introduction of Australia's national rotavirus immunisation programme. J Paediatr Child Health 2011, 47(5):266-270.
47. Field E.J., Vally H., Grimwood K., Lambert S.B. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. Pediatrics 2010, 126(3):e506-e512.
48. Quintanar-Solares M., Yen C., Richardson V., Esparza-Aguilar M., Parashar U.D., Patel M.M. Impact of rotavirus vaccination on diarrhea-related hospitalizations among children <5 years of age in Mexico. Pediatr Infect Dis J 2011, 30(1 (Suppl.)):S11-S15.
49. Levine MM. Etiology and outcomes of acute, moderate and severe diarrheal infections in young children in developing countries: insights from the Global Enteric Multi-center Study (GEMS). Presented at the 6th international conference on vaccines for enteric diseases, Cannes, September 14, 2011; 2011.